How long is the treatment regimen for bedaquiline for drug-resistant tuberculosis?

Bedaquiline (Bedaquiline) is a newly developed drug that has shown significant efficacy in the treatment of multi-drug-resistant tuberculosis. This drug represents a novel therapeutic agent that works through a unique mechanism of action compared to currently available anti-tuberculosis drugs. The efficacy of bedaquiline in shortening the duration of MDR-TB treatment and improving treatment success has been demonstrated. Bedaquiline is included in the all-oral regimen recommended by the World Health Organization as an alternative to injectable treatment for patients with multidrug-resistant tuberculosis.

For adult patients, the recommended dose of bedaquiline is 400 mg (4 of 100 mg tablets or 20 of 20 mg tablets) orally once daily for the first two weeks; then from weeks 3 to 24, the recommended dose is 200 mg (2 of 100 mg tablets or 10 of 20 mg tablets) orally three times weekly. When treatment with bedaquiline is deemed necessary after 24 weeks, treatment may be continued at a dose of 200 mg three times per week.

For pediatric patients, the recommended dose is based on body weight. For patients under 15kg-30kg, the recommended dose for the first two weeks is taken orally once daily200< /span>mg((100mg of 2 tablets or 20mg of < span>10 tablets), and then from weeks 3 to 24 weeks, the recommended dose is 100 mg orally three times a week (100 1 tablet in a pan>mg tablet or 5 tablets in a 20mg tablet); for patients over 30kg, the recommended dose is the same as for adults.

Bedaquiline should be taken with food, and the total duration of treatment is 24 weeks, according to the bedaquiline prescription instructions. When patients 16 years of age and older and weighing at least 30 kg require bedaquiline treatment for more than 24 weeks, treatment may be continued at a dose of 200 mg three times per week. Subsequent treatment should be carried out under the guidance of a doctor.